Latest Cannabidiol Therapies News

Page 1 of 1

Nexalis Therapeutics Launches First Human Trial of IRX-616a for Panic Disorder

Nexalis Therapeutics has initiated dosing in its Phase 1 trial of IRX-616a, a novel cannabidiol inhalation treatment targeting panic disorder. The trial aims to evaluate safety and pharmacokinetics, with dose escalation decisions expected soon.

Ada Torres

19 Mar 2026

Browse the archive

Full archive

Aug 2026 July 2026 June 2026 May 2026 Apr 2026 Mar 2026 Feb 2026 Jan 2026